Indoco Remedies Limited (NSE:INDOCO)
India · Delayed Price · Currency is INR | Market Cap | 19.41B |
| Revenue (ttm) | 17.25B |
| Net Income (ttm) | -1.11B |
| Shares Out | 92.25M |
| EPS (ttm) | -11.34 |
| PE Ratio | n/a |
| Forward PE | 53.77 |
| Dividend | 0.20 (0.09%) |
| Ex-Dividend Date | Sep 4, 2025 |
| Volume | 40,832 |
| Average Volume | 33,273 |
| Open | 215.98 |
| Previous Close | 215.71 |
| Day's Range | 206.27 - 215.98 |
| 52-Week Range | 190.00 - 349.80 |
| Beta | 0.41 |
| RSI | 36.79 |
| Earnings Date | Feb 3, 2026 |
About Indoco Remedies
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibioti... [Read more]
Financial Performance
Financial StatementsNews
Indoco Remedies Ltd (BOM:532612) Q2 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
Indoco Remedies Ltd (BOM:532612) Q2 2026 Earnings Call Highlights: Revenue Growth and Strategic Challenges
Q2 2026 Indoco Remedies Ltd Earnings Call Transcript
Q2 2026 Indoco Remedies Ltd Earnings Call Transcript
Indoco Remedies’ Patalganga API facility clears USFDA inspection with zero observations
Indoco Remedies Limited, a leading Indian pharmaceutical company, announced today that its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai, has successfully p...
Why are Indoco Remedies shares up 2% today? Explained
Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Ab...
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in stren...
Indoco Remedies signs Sale and Leaseback Agreemen for Waluj facility assets
Indoco Remedies Limited has announced a strategic move involving the sale and leaseback of some of its movable assets at its Waluj Facility in Aurangabad, Maharashtra. In a regulatory filing, the comp...
Indoco Remedies Q1 Results: Revenue flat at Rs 42 crore, Net loss of Rs 3.6 crore
Indoco Remedies Limited reported a net loss of Rs 3.64 crore for the quarter ended June 30, 2025 (Q1FY26), compared to a profit of Rs 1.82 crore in the corresponding quarter last year. This marks the ...
Indoco Remedies receives EU GMP certification for sterile drug facility in Goa
Indoco Remedies Ltd has received a Certificate of EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant...
Indoco Remedies launches Ticagrelor tablets in UK through subsidiary
Indoco Remedies Limited has officially launched its Ticagrelor film-coated tablets (90mg) in the United Kingdom through its subsidiary, Indoco Remedies UK Limited, on June 2, 2025. This marks a signif...
Indoco Remedies receives USFDA approval for Generic Allopurinol Tablets USP 200 mg
Indoco Remedies Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP 200 mg. The ...
Indoco Remedies shares drop 6% after US FDA issues Form 483 For Hyderabad CRO unit
Indoco Remedies’ stock fell 6% after its clinical research division, AnaCipher, received a Form 483 from the United States Food and Drug Administration (USFDA). As of 9:18 AM, the shares were trading ...
Indoco’s AnaCipher receives one Form 483 after USFDA inspection
Indoco Remedies Limited (Indoco) proudly announces that its Clinical Research Organisation, AnaCipher, has successfully completed a comprehensive 5-day inspection by the USFDA. The inspection took pla...
Indoco Remedies receives relief as GST department drops proceedings on Rs 15.51 crore tax claim
Indoco Remedies Limited announced that the Goods and Services Tax (GST) Authority has officially dropped proceedings related to a ₹15.51 crore tax claim against the company. The decision was issued by...
Indoco Remedies Q3 FY25 Results: Revenue declines 6.2% YoY to Rs 410.55 crore; Net loss widens to Rs 28.40 crore
Indoco Remedies Limited released its financial results for the quarter ending December 31, 2024 (Q3 FY25), reporting a decline in revenue and a net loss due to increased expenses and operational chall...
Indoco Remedies shares plunge over 7% as Goa facility receives USFDA warning letter
Indoco Remedies’ shares fell sharply by 7.52% today following a significant setback, as the company’s Goa facility, contributing 65-70% of its revenue, received a warning letter from the USFDA. The wa...
Indoco Remedies receives USFDA warning letter for Goa facility
Indoco Remedies has received a warning letter from the USFDA for its Goa facility, following an inspection conducted from July 16-26, 2024. This follows the earlier notification on October 11, 2024, w...
Indoco Remedies stock surges 8% on partnership with Clarity Pharma in the UK
Indoco Remedies witnessed a significant 8% jump in its stock price following the announcement of a strategic distribution partnership with Clarity Pharma, UK. This collaboration is set to launch appro...
Indoco Remedies partners with Clarity Pharma to strengthen UK presence
The partnership combines Indoco’s robust portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma’s extensive distribution network and market expertise.
Indoco Remedies shares down nearly 2% after USFDA classifies Goa facility as ‘Official Action Indicated’
Indoco Remedies saw its shares drop nearly 2% on Monday after receiving an update from the U.S. Food and Drug Administration (USFDA) regarding its Goa Plant-II & III facilities. The USFDA has classifi...
Indoco Remedies stock in focus following USFDA issues OAI classification
Indoco Remedies has received an update from the U.S. Food and Drug Administration (USFDA) regarding its Goa Plant-II & III facilities located in Verna Industrial Area, Goa, following an inspection con...
Indoco Remedies’ Goa Plant-II & III Retains OAI Status After USFDA Inspection
Indoco Remedies Limited announced that its Goa Plant-II & III retained the “Official Action Indicated” (OAI) status following a July 2024 inspection by the U.S. FDA. The facility had received OAI in M...
Indoco Remedies shares surge 3% after company gets USFDA approval for Generic Cetirizine Hydrochloride tablets
Indoco Remedies shares jumped 3% after the company received final approval from the USFDA for its generic version of Cetirizine Hydrochloride Tablets USP, 10 mg. This over-the-counter medication is a ...
Indoco Remedies secures USFDA approval for Generic Cetirizine Hydrochloride tablets
Indoco Remedies Limited has announced that it has received final approval from the USFDA for its generic version of Cetirizine Hydrochloride Tablets USP, 10 mg. This over-the-counter medication is a g...